Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Family Medicine
Disease Category: Kidney Disease
Location: United States, NY

Clinical Trial Details

Overview

Research Study Summary

Velcade Therapy For Severe IgA Nephropathy

Purpose

The Rogosin Institute is conducting a clinical research study to assess the safety and efficacy of Velcade® to treat severe IgA nephropathy. Velcade® is FDA-approved for the treatment of multiple myeloma, not for IgA nephropathy, but it may act on non-cancerous normal plasma cells that produce abnormal antibody proteins. IgA nephropathy is a form of kidney disease where abnormal immunoglobulins type A (IgA), a natural antibody produced in plasma cells to protect infections, accumulate in the kidney and cause irritation and inflammation. There is currently no effective treatment for this condition.

Subjects who are found eligible for the study after the screening visit will be seen at the Weill Cornell Medical College CTSC (Clinical and Translational Science Center) outpatient unit to receive 4 doses (1 cycle) of the study drug through a vein and at The Rogosin Institute Outpatient Clinic for some follow-up visits for approximately forty days. If there is no response as measured by blood and urine analysis after the first cycle, a second cycle will be initiated approximately a month later. Follow-up visits, involving physical examinations, blood and urine collections, will take place monthly thereafter for a total participation in the study of one year. Each visit should take approximately 1 hour. A stipend will be given for each study visit completed. Throughout the study, the principal investigator and study doctors will monitor all the medications taken, regardless of their indication.

You may or may not get direct benefits from this study. The presence of protein in your urine might not get better, or may even get worse during the study. However, new information may be collected that may benefit patients with IgA nephropathy in the future.

To qualify for the study you must:

  • Be over 18 years of age,
  • Have a diagnosis of IgA nephropathy proven by biopsy,
  • Have creatinine clearance (a measure of your kidney function) over or equal to 30 cc/min/1.73 m2,
  • Have protein in the urine (over 1 gram per day),
  • Be on specific high blood pressure medication (known as ACE inhibitors, ARB or renin inhibitors) for at least a month before entering the study,
  • Have normal liver function.

To qualify for the study you must NOT:

  • Have HIV or hepatitis B or C.
  • Have cancer.
  • Be pregnant, or plan on becoming pregnant, or be breastfeeding.

To Learn more
Phase

4

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Choli Hartono, MD, Principal Investigator
The Rogosin Institute
505 East 70th Street
New York, NY 10021
Phone: (212) 746-9708
Fax: (212) 746-8300

View Map

Research Center Information: The Rogosin Institute

CW ID: 170409

Date Last Changed: July 22, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.